Contine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Contine

Property Description
Active ingredient Choline Theophyllinate (Oxtriphylline)
Form Tablets, Capsules, Syrups (oral, systemic)
Pharmacological class Xanthine Bronchodilator Agent
Origin Synthetic small molecule, salt compound

What Type of Medicine is Contine?

Contine is the specific commercial name for a medicinal product containing the active substance Choline Theophyllinate, which is formally classified as a Bronchodilator Agent. This compound belongs to the Xanthine chemical group, a class categorized under ATC Code R03DA02, demonstrating its primary use for obstructive airway diseases. Choline Theophyllinate is a synthetic small molecule derived from the purine family. This substance is a refined chemical salt compound, often identified by the synonym Oxtriphylline, which comprises the active therapeutic component Theophylline bound to the organic base Choline. This specific salt structure is engineered to enhance the drug's solubility and improve its absorption into the body compared to taking the base Theophylline compound alone.


Composition and Available Forms of Choline Theophyllinate

The primary component of Contine is the single-ingredient product, Choline Theophyllinate, formulated into various preparations for oral administration. The medication is delivered in several common dosage forms, including solid preparations such as tablets and capsules, alongside liquid preparations like syrups or elixirs. Theophylline functions as a bronchodilator by relaxing smooth muscle in the bronchial airways. Furthermore, many oral forms are available as sustained-release preparations; this design allows the active substance to be released slowly over an extended period to maintain consistent therapeutic levels.


What is the General Purpose of a Xanthine Bronchodilator?

The general purpose of a xanthine bronchodilator like Contine is to promote the physiological process of bronchodilation, which is the widening of constricted airways. This key action is achieved by causing the relaxation of bronchial smooth muscle surrounding the air passages in the lungs. By reducing the tension and opening the airways, the substance diminishes the resistance to airflow. This systemic effect serves as a fundamental, ongoing therapy to maintain open airways and generally alleviate symptoms of chest tightness and breathlessness by facilitating easier and more comfortable respiration.

Regulatory References

  1. MedlinePlus

What side effects are possible with Contine?

Contine, containing the xanthine derivative Choline Theophyllinate, has a safety profile defined by its active component, Theophylline. The occurrence and severity of documented adverse reactions are closely linked to the concentration of the substance in the bloodstream, reflecting a narrow therapeutic window as emphasized in regulatory documents.


Officially Documented Adverse Reactions

Adverse reactions listed in official labeling primarily affect three major physiological systems:

  • Nervous System Disorders: Documented effects include headache, insomnia (trouble sleeping), restlessness, irritability, and tremors (shakiness). The incidence of these effects is sometimes classified in regulatory sources as not known for general therapeutic use.
  • Gastrointestinal Disorders: Reactions include nausea, vomiting, diarrhea, and abdominal pain.
  • Cardiac Disorders: Adverse effects may include tachycardia (increased heart rate), palpitations, and irregular heartbeats (arrhythmias).

Serious Safety Considerations

Regulatory documents explicitly highlight the potential for serious adverse reactions, particularly when serum concentrations of the active substance are elevated (generally exceeding 20 mu g/mL). These serious events include seizures (which may be intractable and potentially fatal) and ventricular arrhythmias (serious irregular heartbeats). The onset of seizures may not always be preceded by the less severe signs of toxicity.


Safety Restrictions and Population Notes

The medicine is formally contraindicated in patients with known hypersensitivity to Theophylline, a history of active peptic ulcer disease, or a pre-existing seizure disorder. Safety statements also address specific patient populations and external factors:

  • Older Adults and Hepatic Impairment: Older individuals and patients with hepatic impairment (liver disease) may have decreased clearance of the substance, increasing the risk of toxicity.
  • Acute Illness: Conditions such as a fever or acute viral illness can decrease the substance's clearance, which is documented to increase the risk of adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Choline Theophyllinate (Contine) is a potentially severe event documented in regulatory labeling. Documented clinical manifestations often include gastrointestinal effects such as persistent vomiting, nausea, and abdominal pain, along with Central Nervous System (CNS) disturbances like severe headache, restlessness, and tremors. Official labeling also reports metabolic abnormalities like hypokalaemia and hyperglycaemia.

Official sources emphasize the risk of serious and life-threatening systemic outcomes. These include major cardiovascular complications, specifically ventricular tachyarrhythmias and severe hypotension. Neurologically, toxicity may lead to generalized seizures and subsequent acute kidney injury. Increased susceptibility to severe effects is cited for paediatric and geriatric patients, as well as those with hepatic impairment.

Mandated immediate emergency actions are critical. Regulatory guidance strictly requires individuals to seek immediate medical attention or contact emergency services for any suspected overdose. Urgent medical care is specifically required when symptoms involve seizures, cardiac arrhythmias, or uncontrollable vomiting.

The official management approach is symptomatic and supportive. Regulatory documents state that no specific antidote is known for Theophylline toxicity. Treatment involves procedures like the administration of activated charcoal and continuous cardiac and serum Theophylline concentration monitoring.

Therapeutic Uses of Contine

Main Uses of Contine

Contine is a medication primarily prescribed for the management of severe pain that requires continuous, around-the-clock treatment for an extended period. It belongs to the class of medications known as opioid analgesics. Because it is formulated as a controlled-release tablet, it is designed to release the active medicinal ingredient gradually into the bloodstream.

Chronic Pain Management

This medication is typically utilized when other pain management strategies, such as non-opioid medications or immediate-release opioids, do not provide adequate pain relief or are not tolerated. It is specifically intended for chronic conditions where pain is persistent and predictable, such as:

  • Pain associated with advanced-stage malignancies or cancer.
  • Severe musculoskeletal pain that has not responded to conservative treatments.
  • Long-term pain resulting from major physical trauma or extensive surgical procedures.

Mechanism of Action

Contine works by acting on specific receptors in the central nervous system. By binding to these receptors, the medication alters the way the brain and nervous system perceive and respond to pain signals. This process does not eliminate the source of the pain but increases the individual's pain tolerance and decreases the perceived intensity of the discomfort.

Benefits for Patients

The primary objective of treatment with Contine is to improve the quality of life for individuals suffering from debilitating, long-term pain.

Sustained Pain Relief

The controlled-release delivery system is a central feature of this medication. Unlike immediate-release formulations that provide a rapid peak in medication levels followed by a quick decline, this system aims to maintain a steady concentration of the drug in the body. This can result in more consistent pain control throughout the day and night.

Improved Functional Ability

By reducing the burden of constant pain, the medication may help individuals perform daily activities more comfortably. Effective pain management can support better sleep patterns, improved mobility, and a more stable emotional state, which are often disrupted by chronic pain conditions.

Reduction in Dosing Frequency

Due to its extended-release nature, this medication is usually taken less frequently than immediate-acting painkillers. This simplified schedule can be more convenient for patients and may help in maintaining a consistent therapeutic effect without the frequent "ups and downs" associated with short-acting alternatives.

Regulatory References

  1. NIH DailyMed label for Theophylline (Anhydrous)

Eligibility and Restrictions for Use

Who Can and Cannot Use Contine?

The population eligibility for Contine (Choline Theophyllinate/Oxtriphylline) is strictly defined by regulatory documents, distinguishing between groups for whom use is allowed, restricted, or absolutely prohibited.


Contraindicated Populations

Use of this medicine is prohibited for patients with:

  • Known hypersensitivity to xanthine derivatives (the drug class).
  • Active peptic ulcer disease.
  • A history of a seizure disorder or epilepsy.

Populations Requiring Restricted or Conditional Use

Official labeling mandates restricted use and frequent therapeutic monitoring for specific patient groups due to altered drug clearance or increased risk of toxicity:

  • Hepatic Impairment: Patients with liver disease (e.g., cirrhosis) require significant dose reduction, as drug clearance is substantially decreased.
  • Cardiovascular Conditions: Patients with Congestive Heart Failure (CHF) or Cor Pulmonale require careful management and dose adjustment.
  • Older Adults (ge 60 years): Restricted use is necessary because clearance is decreased, increasing the risk of toxicity.
  • Acute Conditions: Patients with sustained Fever or acute viral illness require immediate dose adjustment due to decreased clearance.

Age and Reproductive Eligibility

Category Eligibility Status (Official Wording)
Pediatric Use Approved, but requires weight-based dosing; not recommended in neonates or premature infants.
Pregnancy Conditional Use (e.g., FDA Category C); use is warranted only if the potential benefit justifies the risk.
Lactation Conditional Use; the substance is excreted into breast milk, and infants must be monitored.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Contine, containing Theophylline, exhibits documented pharmacokinetic and pharmacodynamic interactions that must be considered. These interactions can formally alter the plasma concentration of Theophylline or result in compounded effects.

Pharmacokinetic and Exposure Alterations

Many medicines alter Theophylline's clearance, primarily through the inhibition or induction of microsomal enzymes, notably CYP1A2. Substances like Cimetidine, Ciprofloxacin, and Fluvoxamine are documented to decrease Theophylline clearance, leading to a substantial increase in its plasma concentration. Conversely, agents such as Carbamazepine and Rifampin are shown to increase Theophylline clearance, causing a decrease in exposure.

Pharmacodynamic and Substance Interactions

Theophylline acts as an antagonist to Adenosine and can increase the risk of ventricular arrhythmias when co-administered with anesthetics like Halothane. The co-administration of other Xanthine Derivatives is discouraged due to the risk of additive effects. Non-medicinal substances are also documented to affect clearance: Smoking (tobacco or marijuana) officially increases clearance, while a single large dose of alcohol can decrease clearance.

Timing and Population Restrictions

For extended-release forms, regulatory documents mandate that administration (with or without food) must be consistent to prevent fluctuations in blood levels. Furthermore, conditions such as hepatic impairment and high fever are officially noted to reduce Theophylline clearance, intensifying the clinical relevance of all drug-drug interactions.

Mechanism of Action

The mechanism of action for Contine, driven by its active component Theophylline, involves nonselective modulation of cellular signaling, with the resulting action being highly dependent on its concentration. The primary action involves the nonselective inhibition of Phosphodiesterase (PDE) enzymes (e.g., PDE3 and PDE4) and nonselective antagonism of Adenosine Receptors. By inhibiting PDE, the drug prevents the breakdown of cyclic AMP (cAMP), leading to its accumulation inside cells. This molecular cascade results in the relaxation of smooth muscle surrounding the airways, leading to a reduction in airflow resistance. Contine engages a separate, concentration-dependent mechanism by acting as an activator of Histone Deacetylase-2 (HDAC2) and an inhibitor of PI3K-delta. This process contributes to the modulation of chronic inflammatory gene transcription and the stabilization of the cellular environment within the airways. Additionally, Adenosine Receptor antagonism in the central nervous system contributes to the stimulation of central respiratory neuron firing. Separately, the drug's interaction with Calcium-activated Potassium Channels on vagal sensory nerves reduces their excitability, leading to the inhibition of the neurogenic cough reflex signal.

Dosage and Administration Information

How to Use Contine: Official Administration Guidelines

Contine, which contains the active substance Choline Theophyllinate (Theophylline), is prescribed for chronic use and must be administered according to specific, standardized protocols.

Administration Scope and Forms

Feature Official Guideline
Route of Administration Oral administration only (tablets, capsules, syrups).
Approved Forms Available as immediate-release (liquid) and extended-release (ER) tablets/capsules for once- or twice-daily dosing.

Dosing, Titration, and Monitoring

Dosage is not fixed; it is individually adjusted based on laboratory confirmation of the drug concentration in the patient’s bloodstream. This practice is essential due to theophylline's narrow therapeutic index.

Feature Official Guideline
Target Serum Concentration Dosing must be titrated to maintain a peak serum theophylline concentration between 10 to 15 mug/mL.
Adult Maximum Dose The maximum total daily dose for otherwise healthy, non-smoking adults is generally 600 mg (Theophylline equivalent).
Dose Adjustment Dose increments, when necessary, must be made at intervals of no less than three days to allow blood levels to reach a new steady state.

Administration Instructions for Proper Use

  • Extended-Release Forms: ER tablets must be swallowed whole and not broken, crushed, or chewed to prevent rapid drug release (dose dumping).
  • Food Relationship: ER formulations may generally be taken with or without food. However, patients should follow the specific instructions for their brand, as high-fat meals can alter absorption.
  • Missed Dose: If a dose is missed, it should be skipped. The next dose should be taken at the regularly scheduled time, and the patient must not take a double dose to compensate.
  • Older Adults: A lower maximum dose is often specified for older adults, typically not exceeding 400 mg per day.

Recent Clinical Evidence

Contine: Recent Clinical Evidence

Evidence for Use in Stable Chronic Obstructive Pulmonary Disease (COPD)

Research has explored Contine (Choline Theophyllinate) primarily as a substance that was evaluated for its role in managing Stable Chronic Obstructive Pulmonary Disease (COPD), a condition marked by functional limitations and periods of heightened symptoms. The evidence base includes meta-analyses of randomized, placebo-controlled clinical trials, alongside large, long-term observational studies. Trials comparing the drug to placebo tracked changes in objective lung function measures, such as Forced Expiratory Volume in 1 second (FEV1).

However, the findings were mixed when research examined the specific long-term outcomes related to the frequency of COPD flare-ups (exacerbations), especially when the drug was studied for use as an add-on therapy to modern standard-of-care inhalers. The level of certainty remains low regarding the consistency of findings related to acute episode frequency in this context, and comparative evidence is lacking against newer bronchodilator classes.


Evidence for Use in Long-Term Control of Chronic Asthma

Contine was studied for the long-term symptomatic control of Chronic Bronchial Asthma, a condition presenting with cycles of stability and flare-ups. Research includes many randomized controlled trials that were used in research exploring short-term or episodic symptom patterns. Studies monitored functional measures, such as Peak Expiratory Flow Rate (PEFR), and patient-reported outcomes describing perceived discomfort.

Studies monitored changes in airway function and reported patterns observed during the study period when compared to placebo. However, a significant portion of the foundational evidence is older, meaning long-term effects are not fully established when comparing the drug against modern, guideline-recommended inhaled therapies. Data for certain groups, such as those with specific severe disease, remain insufficient.


Evidence in Specific Patient Groups and Limitations

The drug was evaluated in studies for various populations, including trials specifically focusing on adults with COPD and asthma. The evidence base also contains research that was studied for use in children with chronic asthma, where studies monitored changes in functional measures. In older adults with COPD, results apply only to the populations studied, and data for certain groups remain insufficient.

While some studies provide insight into short-term changes, follow-up durations were limited in the high-quality randomized trial setting. The evidence quality varies across studies, and key limitations are observed in the research concerning the consistency of findings for preventing exacerbations.

Key Studies & References

  1. NIH DailyMed Label for Theophylline (Anhydrous) - Primary Role and Indicated Conditions
  2. MedlinePlus Drug Information: Theophylline (Bronchodilator Mechanism and Dosage Forms)

Frequently Asked Questions (FAQ)

Common questions about Contine (FAQ)

Q: Is Contine the same type of medicine as [similar generic name]?

Contine contains Choline Theophyllinate, and it is officially classified as a Xanthine Bronchodilator Agent. This classification defines its specific chemical family and mechanism of action, which is distinct from other classes of medicines used for similar conditions.


Q: Can Contine be split or crushed before taking it?

Official administration instructions state that extended-release tablets or capsules of Contine must be swallowed whole. Breaking or crushing them can compromise the extended-release function, potentially leading to an unintended release rate of the drug.


Q: Is Contine suitable for people with kidney problems?

Regulatory warnings indicate that Contine's active substance requires cautious use and careful monitoring in patients who have renal impairment (kidney disease). This is because kidney function can affect the body's clearance of the substance, increasing the risk of adverse effects.


Q: Does taking Contine with food change how it works?

For extended-release forms, the official advice is that while they can generally be taken with or without food, administration is noted to require consistency. Some studies suggest high-fat meals may alter the rate at which the substance is absorbed. Immediate-release liquid forms typically do not have specific food restrictions.


Q: What is the half-life of Contine?

The half-life, which is the time it takes for the concentration of the substance to be reduced by half in the body, is typically in the range of 5 to 10 hours in healthy, non-smoking adults. Because this value can vary significantly based on individual factors, official guidance requires close blood level monitoring to maintain concentrations within the specified therapeutic range.


Q: How quickly does Contine usually start working?

Contine's immediate-release forms begin to relieve symptoms relatively quickly. However, according to product information, the drug is primarily classified as a long-term control medicine, and official guidance focuses on maintaining a consistent amount in the bloodstream for chronic management.


Q: How long do the effects of Contine last after taking it?

The duration of the effect is related to the specific form being used. Standard or immediate-release forms are typically administered every 6 to 8 hours, whereas the extended-release (ER) preparations are designed to maintain therapeutic effects for up to 12 or 24 hours.


Q: Is Contine known to affect sleep patterns?

Official safety documentation lists nervous system disorders, including insomnia (trouble sleeping) and restlessness, as possible side effects. These effects are associated with the stimulant properties of the drug's active substance.


Q: Can Contine be taken with pain relievers like paracetamol or ibuprofen?

Official drug interaction lists generally do not document major conflicts that prohibit the use of Contine with common over-the-counter pain relievers such as paracetamol or ibuprofen. Official guidance emphasizes the importance of informing healthcare providers about all medicines being used.


Q: Does Contine interact with caffeine or alcohol?

Official documents confirm that both caffeine and alcohol can influence the substance's effect. Caffeine is structurally similar and may increase the risk of side effects like tremors. A single large dose of alcohol is officially noted to potentially decrease the clearance of the substance from the body.


Q: Is it okay to use Contine if I have [a general health condition, e.g., high blood pressure]?

The official documentation provides specific warnings for its use. Certain conditions, such as uncontrolled high blood pressure or heart failure, are noted in labeling as requiring careful management and monitoring due to potential complications.


Q: Are there any specific foods or drinks to avoid while taking Contine?

Official product information does not list specific foods or drinks that are strictly prohibited. However, beyond the rule that high-fat meals may alter ER absorption, some sources suggest limiting the intake of substances containing caffeine.


Q: Is Contine safe for older adults to use?

Use is subject to restrictions in older adults (aged 60 years and above), as regulatory documents note that drug clearance is decreased in this population. This means there is an increased potential for toxicity, and therefore, a lower maximum daily dose is typically specified.


Q: Can women who are planning pregnancy use Contine?

Contine falls under a Conditional Use classification for pregnancy. Official guidance advises that use is warranted only if the potential benefit justifies the risk, and this assessment is made by a healthcare provider.


Q: What does the research say about the long-term use of Contine?

Reviews of the clinical evidence indicate that much of the foundational research is older, and follow-up periods in high-quality trials were often limited. For this reason, official sources state that the long-term effects of Contine, especially when compared to newer therapies, are not fully established in all patient groups.


Q: Is Contine generally considered a long-term or short-term treatment?

Contine is officially classified and prescribed as a long-term control medicine. Its purpose is for chronic, daily use to maintain consistent management of the condition rather than for providing immediate, short-term relief.


Q: Is it true that Contine can cause dizziness?

Yes, dizziness is listed as one of the officially documented adverse reactions that can affect the nervous system.


Q: How is Contine related to the [drug class, e.g., 'antihistamine' or 'SSRI'] group of medicines?

Contine's active component belongs to the Xanthine chemical group. This makes it a Bronchodilator Agent, a class that acts distinctly from medicines such as antihistamines or SSRIs.


Q: Are there any known interactions between Contine and common supplements (like vitamins or herbal products)?

Official guidance emphasizes the importance of disclosing all medicines being used, including vitamins, minerals, and herbal supplements. This is due to the potential for supplements to affect how the substance is metabolized in the body.


Q: What is Contine's safety classification for breastfeeding?

Official labeling lists use during lactation as Conditional Use. The substance is known to be excreted into breast milk, and regulatory guidance advises that if the medicine is used, the infant should be monitored for any signs of side effects.


Q: Do studies show that Contine works differently in children compared to adults?

Studies have shown that children typically eliminate the active substance more rapidly than adults due to differences in metabolism. This difference means that dose selection for pediatric use requires careful calculation based on body weight.


Q: Why does the packaging for Contine include a specific warning about operating machinery?

Warnings about operating machinery are required because Contine's documented side effects include effects on the central nervous system, such as tremors, dizziness, restlessness, and insomnia. These documented effects could potentially impair a person's ability to perform tasks like driving or operating heavy equipment safely.


Q: What are the limitations or restrictions on who can use Contine?

Contine is strictly prohibited for patients with a known history of a seizure disorder, active peptic ulcer disease, or hypersensitivity to the drug class. Conditional use, requiring monitoring, applies to those with liver disease, high fever, or certain cardiovascular conditions.


Q: Does Contine have any known effects on mood or anxiety?

Official adverse reaction reports for nervous system disorders include effects such as irritability and restlessness. These psychological effects are associated with the stimulant nature of the active substance.


Q: What kind of evidence led to Contine's approval by regulatory bodies?

The evidence reviewed by regulatory bodies consisted primarily of data from randomized, placebo-controlled clinical trials. These studies focused on tracking changes in objective lung function measures, such as Forced Expiratory Volume in 1 second (FEV1), to assess the drug's effect.


Q: What happens if Contine is taken at a higher dose than recommended?

If the active substance reaches elevated concentrations in the bloodstream, official safety warnings indicate an explicit potential for serious adverse reactions. These serious events may include seizures and life-threatening ventricular arrhythmias (irregular heartbeats).


Q: Is Contine associated with headaches or migraines?

Yes, headache is listed among the officially documented adverse reactions that can affect the nervous system.


Q: What is the research status of Contine for new potential uses?

Research has primarily focused on its officially approved uses for COPD and Chronic Asthma. Regulatory literature confirms that studies continue to explore the drug’s profile, including its use as an add-on therapy and its effectiveness in various patient groups.


Q: Can Contine interact with hormonal contraceptives?

Yes, official regulatory documents indicate that contraceptive steroids (hormonal contraceptives) may affect how the body processes the substance. This interaction can potentially increase the concentration of the active substance in the blood, often requiring monitoring.

How should Contine be stored and disposed of?

How to Store and Dispose of Contine

Contine must be stored at Controlled Room Temperature, typically between 20 C to 25 C (68 F to 77 F). The medication must be protected from light, moisture, and excessive heat, and should never be allowed to freeze.

Storage and Handling

It is required to keep Contine in a tightly closed, light-resistant container and strictly out of the reach of children. The container should feature a child-resistant closure.

Disposal

Expired or unused Contine must be disposed of according to official guidelines, such as utilizing a drug take-back program. Disposal by flushing down the toilet or pouring into a drain is generally prohibited to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Contine found in:

A-Z Index: